Follicular Lymphoma

Follicular Lymphoma Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Featured

In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.

Carla Casulo, MD, Talks About the Role of Observation in Treating FL

Dr Casulo discusses the role that observation plays in the treatment of patients with FL.

Targeting EZH2 in the Context of Follicular Lymphoma

Peter Martin, MD, discusses recent advancements in the treatment of patients with EZH2-positive FL.

Peter Martin, MD, Discusses the Value of PET/CT Status in FL

Peter Martin, MD, provides an overview of 2 clinical studies that explored the prognostic value and involvement of PET/CT status in patients with FL.

Obinutuzumab Plus Venetoclax Well-Tolerated in Previously Untreated FL

Peter Martin, MD, discussed the findings and clinical significance of the SAKK 35/15 clinical trial.

Novel Allogeneic CAR-T Products Appear Safe in LBCL and FL

Sattva Neelapu, MD, discusses early results from the ALPHA study suggesting that ALLO-501 and ALLO-647 are safe and may be effective in LBCL and FL.

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

How I Practice Now: Treating FL During the Global Pandemic

John Allan, MD, explains the impact the COVID-19 pandemic has had on the treatment of patients with follicular lymphoma and other indolent lymphomas.

Ibrutinib Plus Rituximab Demonstrates Activity in Frontline FL

Nathan Fowler, MD, discusses the results of of phase 2 study that evaluated the activity and safety of ibrutinib in combination with rituximab in untreated FL.